Table 2 Frequencies of EOB-MRI features

LI-RADS v2018 feature^a

 Size, cm

2.6 (1.6–3.6)

2.8 (1.7–4.0)

0.200

2.8 (1.8–3.8)

2.4 (1.6–3.2)

0.317

 Nonrim arterial phase hyperenhancement

90 (91.8)

25 (83.3)

0.316

38 (90.5)

11 (91.7)

1.000

 Nonperipheral "washout"

87 (88.8)

26 (86.7)

1.000

8 (19.0)

0 (0.0)

0.239

 Enhancing "capsule"

71 (72.4)

21 (70.0)

0.794

32 (76.2)

9 (75.0)

1.000

 Corona enhancement

24 (24.5)

7 (23.3)

0.897

12 (28.6)

3 (25.0)

1.000

 Fat sparing in solid mass

8 (8.2)

5 (16.7)

0.316

0 (0.0)

1 (8.3)

0.222

 Diffusion restriction

97 (99.0)

30 (100.0)

1.000

42 (100.0)

12 (100.0)

–

 Mild-moderate T2 hyperintensity

95 (96.9)

30 (100.0)

1.000

41 (97.6)

11 (91.7)

0.398

 Iron sparing in solid mass

24 (24.5)

4 (13.3)

0.196

9 (21.4)

2 (16.7)

1.000

 Transitional phase hypointensity

93 (94.9)

30 (100.0)

0.469

40 (95.2)

12 (100.0)

1.000

 Hepatobiliary phase hypointensity

92 (93.9)

29 (96.7)

0.897

42 (100.0)

12 (100.0)

–

 Nonenhancing "capsule"

13 (13.3)

2 (6.7)

0.510

7 (16.7)

1 (8.3)

0.798

 Nodule-in-nodule

24 (24.5)

9 (30.0)

0.546

6 (14.3)

2 (16.7)

1.000

 Mosaic architecture

16 (16.3)

6 (20.0)

0.641

4 (9.5)

2 (16.7)

0.862

 Fat in mass, more than adjacent liver

41 (41.8)

14 (46.7)

0.640

23 (54.8)

7 (58.3)

0.826

 Blood products in mass

19 (19.4)

4 (13.3)

0.450

5 (11.9)

3 (25.0)

0.506

 Iron in mass, more than liver

3 (3.1)

1 (3.3)

1.000

0 (0.0)

0 (0.0)

–

 Marked T2 hyperintensity

2 (2.0)

0 (0.0)

1.000

0 (0.0)

1 (8.3)

0.222

 Hepatobiliary phase isointensity

5 (5.1)

1 (3.3)

1.000

0 (0.0)

0 (0.0)

–

 Tumor in vein

2 (2.0)

1 (3.3)

0.554

1 (2.4)

0 (0.0)

1.000

 Rim arterial phase hyperenhancement

3 (3.1)

5 (16.7)

0.024*

4 (9.5)

0 (0.0)

0.564

 Peripheral "washout"

1 (1.0)

0 (0.0)

1.000

0 (0.0)

0 (0.0)

–

 Delayed central enhancement

0 (0.0)

0 (0.0)

–

1 (2.4)

0 (0.0)

1.000

 Targetoid TP or HBP appearance

1 (1.0)

1 (3.3)

0.415

0 (0.0)

0 (0.0)

–

 Infiltrative appearance

12 (12.2)

3 (10.0)

0.992

2 (4.8)

0 (0.0)

1.000

 Marked diffusion restriction

32 (32.7)

16 (53.3)

0.041*

13 (31.0)

6 (50.0)

0.381

 Necrosis or severe ischemia

15 (15.3)

2 (6.7)

0.361

6 (14.3)

2 (16.7)

1.000

 LR-M category

3 (3.1)

6 (20.0)

0.006*

3 (7.1)

0 (0.0)

1.000

 LR-TIV category

2 (2.0)

1 (3.3)

0.554

1 (2.4)

0 (0.0)

1.000

 LR-3 category

1 (1.0)

0 (0.0)

1.000

0 (0.0)

0 (0.0)

–

 LR-4 category

9 (9.2)

2 (6.7)

0.954

3 (7.1)

1 (8.3)

1.000

 LR-5 category

83 (84.7)

21 (70.0)

0.071

35 (83.3)

11 (91.7)

0.798

Other imaging feature

 Liver surface retraction

2 (2.0)

0 (0.0)

1.000

0 (0.0)

1 (8.3)

0.222

 Adjacent biliary dilatation

1 (1.0)

1 (3.3)

0.415

0 (0.0)

1 (8.3)

0.222

 Radiologic cirrhosis

60 (61.2)

19 (63.3)

0.835

24 (57.1)

6 (50.0)

0.661

 Bilobar involvement

4 (4.1)

3 (10.0)

0.430

4 (9.5)

0 (0.0)

0.564

 Internal artery

13 (13.3)

3 (10.0)

0.875

5 (11.9)

1 (8.3)

1.000

 Non-smooth tumor margin

49 (50.0)

17 (56.7)

0.523

21 (50.0)

4 (33.3)

0.307

 Peritumoral hypointensity on PVP

18 (18.4)

4 (13.3)

0.523

3 (7.1)

2 (16.7)

0.661

 Peritumoral hypointensity on TP

16 (16.3)

3 (10.0)

0.576

3 (7.1)

2 (16.7)

0.661

 Peritumoral hypointensity on HBP

25 (25.5)

11 (36.7)

0.234

7 (16.7)

1 (8.3)

0.798

 Marked HBP hypointensity

12 (12.2)

19 (63.3)

 < 0.001*

4 (9.5)

8 (66.7)

 < 0.001*

 Single nodular type growth

71 (72.4)

19 (63.3)

0.339

15 (35.7)

4 (33.3)

1.000

 Peritumoral hyperintensity on T2WI

7 (7.1)

5 (16.7)

0.227

2 (4.8)

0 (0.0)

1.000

 Non-hypervascular HBP hypointense

 Nodules

19 (19.4)

8 (26.7)

0.393

17 (40.5)

4 (33.3)

0.911